| Cat. No. |
Product Name |
Information |
| PC-45995 |
Mutated EGFR-IN-1
EGFR inhibitor
|
Mutated EGFR-IN-1 is an analogue of AZD9291 that is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. |
| PC-23313 |
TAK-285
HER2/EGFR inhibitor
|
TAK-285 is a potent, dual inhibitor of HER2 and EGFR (HER1) with IC50 of 17 nM and 23 nM, respectively. |
| PC-22888 |
DS06652923
EGFR C797S inhibitor
|
DS06652923 is a potent, and orally available EGFR-triple-mutant inhibitor with IC50 of 2.0 nM, 0.89 nM and 6.0 nM for del19/T790M/C797S, L858R/T790M/C797S and WT EGFR resceptively. |
| PC-22843 |
Arglabin
EGFR inhibitor
|
Arglabin is a sesquiterpene lactone from the Chinese herb Artemisia myriantha Wall. (Asteraceae), shows anti-inflammatory and antitumor activities, inhibits the EGFR downstream signaling pathways mTORC1 and mTORC2. |
| PC-22389 |
AZ14133346
EGFR Ex20Ins inhibitor
|
AZ14133346 is a potent and selective inhibitor of EGFR Ex20Ins with enzyme IC50 of <3 nM and cell IC50 of 85 nM, 14-fold selective over wild-type EGFR (cell IC50=1200 nM). |
| PC-22088 |
Icotinib hydrochloride
EGFR inhibitor
|
Icotinib hydrochloride (BPI-2009H) is a potent and specific EGFR inhibitor with IC50 of 5 nM, also inhibits mutant EGFRL858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q. |
| PC-22087 |
Icotinib
EGFR inhibitor
|
Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with IC50 of 5 nM, also inhibits mutant EGFRL858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q. |
| PC-21851 |
DDC4002
mutant EGFR inhibitor
|
DDC4002 is a potent, selective and allosteric EGFR inhibitor, shows selectivity against L858R/T790M/C797S EGFR mutants with IC50 of 39-50 nM, does not inhibit WT EGFR. |
| PC-21850 |
EAI001
mutant EGFR inhibitor
|
EAI001 is a potent, mutant-selectiveepidermal growth factor receptor (EGFR) allosteric inhibitor with IC50 value of 24 nM for EGFRL858R/T790M. |
| PC-21841 |
AG1478
EGFR inhibitor
|
AG1478 (Tyrphostin AG-1478) is a potent, selective EGFR tyrosine kinase inhibitor with IC50 of 3 nM. |
| PC-21566 |
BDTX-1535
EGFR inhibitor
|
BDTX-1535 is a 4th generation, irreversible, CNS penetrant, potent, wild type sparing EGFR inhibitor, targets a family of oncogenic EGFR extracellular domain alterations and amplification in GBM, and EGFR resistance mutations in NSCLC. |
| PC-21465 |
BI-8128
EGFR inhibitor
|
BI-8128 is a potent, selective, reversible and orally bioavailable fourth generation EGFR inhibitor, potently inhibits oncogenic EGFR variants del19 and L858R as well as the acquired EGFR resistance mutations T790M and C797S. |
